Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain Syndrome

NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
September 19, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference

NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
September 06, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
September 02, 2016 16:47 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Transition of Chief Medical Officer

NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
August 09, 2016 17:30 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2016 Financial Results

NEW YORK, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
July 05, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

NEW YORK, July 05, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
June 27, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes

NEW YORK, June 27, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
June 13, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference

NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
May 11, 2016 16:42 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports First Quarter 2016 Financial Results

NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
May 03, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions

NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...

keyboard_arrow_left Previous Page